Abstract Despite the role of vitamin D 3 endocrine system in prevention of mammary gland transformation in animal models, use of 1,25(OH) 2 D 3 in clinical settings is precluded due to its toxicity in vivo. Therefore much effort has been placed in developing relatively non-toxic vitamin D analogs. Recently, with the discovery of the expression of 25-hydroxy vitamin D 3 1a-hydroxylase (CYP27B1) in multiple extrarenal organs, the functional role of prohormone, 25-hydroxyvitamin D 3 [25(OH)D 3 ], has been redefined. Since 25(OH)D 3 does not cause hypercalcemia and maintains relative high concentration in serum, it is possible that the prohormone can be converted to active hormone in mammary epithelial cells to provide chemopreventive effects. In the present study, we evaluated its functional significance using mouse mammary organ culture (MMOC) system. We first showed that 25(OH)D 3 1a-hydroxylase is extensively expressed in mammary ductal epithelial cells at both protein and mRNA levels, which is a prerequisite for 25(OH)D 3 to function in an autocrine/paracrine manner. However, we also observed that clotrimazol (1a-hydroxylase inhibitor) enhanced 25(OH)D 3 -induced CYP24 expression in breast cancer cells. In mammary glands derived from 1a-hydroxylase knockout mice, 25(OH)D 3 treatment in organ culture significantly induced CYP24 expression, indicating a potential direct effect of 25(OH)D 3 . In MMOC, 100-250 nM 25(OH)D 3 suppressed both ovarian hormone-dependent and -independent mammary precancerous lesions (induced by DMBA) by more than 50%, while the active hormone 1,25(OH) 2 D 3 (positive control) at 100 nM suppressed alveolar lesions by more than 80%. The inactive vitamin D 3 (negative control) at 100 nM suppressed alveolar lesions by only 20% (P [ 0.05). We found that 25(OH)D 3 inhibits DMBA-induced mammary alveolar lesions (MAL) in a stage-specific manner: 25(OH)D 3 mainly inhibits the promotion stage of lesion formation. We conclude that 25(OH)D 3 could serve as a non-toxic natural chemopreventive agent for further development for breast cancer prevention.
Introduction
The role of vitamin D and its analogs in prevention of mammary gland transformation in animal model has been well established, but the majority of the effective vitamin D analogs are precluded in clinical settings due to its toxicity in vivo. Consequently, much attention was paid to developing safe and less calcemic analogs of 1,25(OH) 2 D 3 that would have desirable growth modulatory effects. Outstanding examples of such promising analogs include EB-1089 [1] [2] [3] , KH-1060 [3] , MC-903 [1] , Gemini compounds [4] and 1a(OH)D 5 [5, 6] . New analogs are continually being synthesized and evaluated in experimental models. Although a few of these analogs have shown potential for use in chemoprevention or therapy of breast cancer, almost all of the synthetic analogs are more or less toxic at a pharmacological dose, limiting its application in clinical use.
Epidemiological studies have supported the negative association of breast, prostate, and colon cancer risk as well as mortality rates with annual sunlight exposure and serum vitamin D 3 (25(OH)D 3 ) levels in different geographical areas [7] [8] [9] [10] [11] . With the discovery that 25-hydroxy vitamin D 3 1a-hydroxylase (CYP27B1) is expressed in multiple vitamin D target tissues including pancreas, colon, breast and prostate [12] [13] [14] [15] , it is possible that 25(OH)D 3 , the major vitamin D metabolite present at much higher concentration in serum in comparison to that of 1,25(OH) 2 D 3 [16] , may serve as a natural chemoprotective vitamin D in the body. 25(OH)D 3 can be locally converted to the active 1,25(OH) 2 , which is highly expressed in renal proximal tubules. CYP27B1 protein is the key enzyme in the two-step activation process of inactive 25(OH)D 3 to active 1,25(OH) 2 D 3 . CYP27B1 was initially proved to be the 1a-hydroxylase found in proximal renal tubules that carries out the 1a-hydroxylation of 25(OH)D 3 and is the enzyme that is defective in vitamin D dependent rickets (VDDR) type 1 [18] . Recently 1a-hydroxylase has been shown to be expressed in various extrarenal sites in the body including mammary gland [12] [13] [14] [15] . However, very limited information on CYP27B1 expression and regulation is available for mammary gland. Zinser et al [12] reported that CYP27B1 mRNA was low but detectable in virgin mammary glands from wild-type mice and increased *20-fold by day 9 of pregnancy. CYP27B1 protein was also detectable in MCF-7 and T47D breast cancer cells [12] . The CYP27B1 protein was expressed at comparable levels in mammary glands from WT and VDR knockout mice during pregnancy and lactation. Friedrich et al showed upregulated CYP27B1 mRNA in breast carcinomas as compared to normal tissue [14] . Since CYP27B1 is locally expressed in breast epithelial cells, 25(OH)D 3 , a natural nontoxic vitamin D metabolite which is present at high concentration in serum, could be developed as an ideal, natural cancer chemoprenventive agent. Here we show the functional significance of 25(OH)D 3 at physiological concentration on the expression of 1a-hydroxylase and its chemopreventive effect using mouse mammary organ culture system. There are two protocols to induce precancerous mammary lesions in the mammary glands of immature mice. The glands can either develop mammary alveolar lesions (MAL) or mammary ductal lesions (MDL), depending upon the steroid hormone combination present in the medium. If the glands are incubated in the presence of 17b-estradiol and progesterone, they develop MDL [19] , whereas if estrogen and progesterone are replaced with glucocorticoids, they develop MAL. The entire procedure was described in detail previously [20] and summarized in Fig. 1 . Briefly, thoracic pairs of mammary glands from Balb/c mice pretreated with 1 lg estradiol and 1 mg progesterone for 9 days are removed under sterile conditions and floated on silk rafts in Waymouth's serum-free media supplemented with IPAF (Insulin + prolactin + aldosterone + hydrocortisone) or IPEPg (Insulin + prolactin + estradiol + progesterone). On day 3, glands are treated with 2 lg/ml DMBA for 24 h to induce precancerous lesions, and continued to culture in the same media for another 6 days. After 10 days' culture, the glands are transferred to a medium containing insulin alone for additional 14 days. Vitamin D metabolites (100-500 nM 25(OH)D 3 , 100 nM 1,25(OH) 2 D 3 are included in the culture for various time during the 10 day of growth phase ( Fig. 1) depending on treatment protocol. For Fig. 1 Protocol for mammary gland organ culture. Thoracic pairs of the mammary glands were removed from female BALB/c mice pretreated for 9 days with estrogen (E) (1 lg/mouse) plus progesterone (Pg) (1 mg/mouse). Glands were incubated with IPAH (5 lg/ml insulin + 5 lg/ml prolactin + 1 lg/ml aldosterone + 1 lg/ml hydrocortisone) or IPEPg (I + P + E + Pg) for 10 days and with 7,12-dimethylbenz[a]-anthracene (DMBA) at a dose of 2 lg/ml for 24 h on the 3rd day. Vitamin D metabolites are included either from day 0 to day 10 or day 0 to day 4 (initiation phase) or day 4 to day 10 (promotion phase). Glands respond to the presence of hormones by developing MAL or MDA. After 10 days in growth promoting hormones, the glands are incubated for an additional 14 days in the medium containing only insulin, which allows the regression of normal structures, whereas glands incubated with DMBA do not fully regress, some area attain altered hormonal requirements and termed MAL or MDL stage specific effect, vitamin D metabolites were included in culture from day 0-4 to observe the anti-initiation effect, and from day 4-10 to observe the anti-promotion effect. For morphological observation of MAL, the glands were fixed and stained with alum carmine for evaluation of incidence as described previously [19] . The glands for MDL are fixed in formalin for 24 h and processed for histopathological evaluation. The glands are divided into several microscopic fields and each field is analyzed for ductal sections; the ducts containing lesions are compared with the total number of ductal fields counted to determine the incidence of MDL.
Materials and methods

Vitamin
Mammary glands from CYP27B1KO mice [21] were cultured using standard MMOC protocol as described above with some modifications. The studies were designed to make paired comparisons. A thoracic pair of mammary glands from the mouse were isolated and cultured separately, one served as a control for vehicle treatment, the other one was treated with 25(OH)D 3 for 24 h. Paired comparison was made between glands from the same mouse.
Cell culture T47D was purchased from American Type Tissue Collection (Manassas, VA) and cultured in MEM containing 10% FBS and supplemented with Non-essential amino acids and antibiotics. When cells reached 70% confluence, serum concentration was decreased to 2% and cells were treated with vitamin D metabolites for 24 h and samples were subjected to qRT-PCR analysis as described previously [22] .
Immunostaining for 25-hydroxy vitamin D 3 1a-hydroxylase Mammary glands cultured in Waymouth's serum-free media supplemented with IPEPg and exposed to Vehicle (Control), DMBA, or DMBA + 25(OH)D 3 were fixed in buffered formalin, and 5 lm-thick sections were prepared for immunostaining using standard protocol as described previously [5] . Sheep-anti-murine 25-hydroxyvitamin D 3 -1a-hydroxylase antibody was purchased from the Binding Sites (San Diego, CA). Donkey anti-sheep secondary antibody was purchased form Santa Cruz Biotechnology Inc (Santa Cruz, CA).
qRT-PCR analysis of CYP27B1 and CYP24 mRNA expression in cultured mouse mammary organs Mouse mammary organs were prepared as described above. The thoracic (for Balb/c and CYP27B1KO C57 mice) and abdominal pairs (for Balb/c) of mammary glands were cultured in medium supplemented with IPAF for 48 h. On the third day the culture was treated with 0.001% Ethanol, 250 nM 25(OH)D 3 or 10 nM 1,25(OH) 2 D 3 for 24 h and mammary glands were collected and stored in trizol reagent (Invitrogen) at -80°C. Total RNA was extracted from each individual organ per manufacturer's instruction. qRT-PCR was conducted as previously described [22] . Mouse hypoxanthine ribosyltransferase (mHPRT) was used as a house keeping gene for normalization [23] , which is expressed at relatively stable level from organ to organ. Primers used for real time PCR are: mCYP24 (forward:
Statistical analysis
Statistical significance was determined by the v 2 analysis for the incidence of MAL and MDL in MMOC experiments. For qRT-PCR analysis of mammary glands obtained after MMOC, experiments were repeated at least twice, data from individual organs per treatment were analyzed for statistical significance using student's t-test. P-value \ 0.05 was taken as significant. For MMOC samples from CYP27B1KO mice, paired comparison was made using student's t-test. Effect of 25(OH)D 3 on CYP24 expression in cultured mammary glands isolated from CYP27B1KO mice and in breast cancer cells in presence of 1a-hydroxylase inhibitor, clotrimazol cAlthough 1a-hydroxylase is extensively expressed in ductal epithelial cells, considering the high level of 25(OH)D 3 in serum, we asked whether 25(OH)D 3 , without being converted to 1,25(OH) 2 D 3 , has direct interaction with VDR. We conducted MMOC using mammary glands isolated from CYP27B1KO mice. The experiments were conducted to provide results on paired comparisions in order to decrease the variance in the results. As shown in Fig. 3a , 250 nM 25(OH)D 3 treatment of CYP27B1KO glands for 24 h increased CYP24 mRNA expression by 5145 ± 1247 (SEM) Fig. 2 Representative examples of expression of 25-hydroxyvitamin D 3 1a-hydroxylase in cultured mouse mammary glands and effect of 25(OH)D 3 on CYP27B1 mRNA expression at organ level. Mammary glands were cultured using the standard protocol for MDL, then fixed and processed for immunohistochemistry for 25-hydroxyvitamin D 3 1a-hydroxylase. Increased expression 1a-hydroxylase was observed after the glands were exposed to DMBA in the presence of 25(OH)D 3 (d). (a) Negative control, primary antibody was not included in the immunostaining process; (b) control treatments, mammary glands were not exposed to carcinogen and 25(OH)D 3 , (c) mammary glands were exposed to DMBA only on day 3 using the standard protocol for MDL; (d) mammary glands were exposed to DMBA on day 3 in the presence of 25(OH)D 3 (day 0-10). (e) and (f), CYP24 and CYP27B1 mRNA expression in cultured mouse mammary glands in response to 25(OH)D 3 . Mammary glands were treated for 24 h with ethanol (control) or 250 nM 25(OH)D 3 and total RNA was extracted from whole organs and subjected to qRT-PCR analysis. CYP24 (e) or CYP27B1 (f) mRNA levels in each gland were normalized to HPRT and the lowest basal level in control glands (the lowest basal level in control glands was set as 1). Data are expressed as mean ± SEM, (n = 20) *P \ 0.05, ***P \ 0.001 in comparison to control fold (P \ 0.01, n = 9) as evaluated by qRT-PCR; whereas 1,25(OH) 2 D 3 (10 nM) increased CYP24 mRNA expression by 2783 ± 727 (SEM) fold (P \ 0.01, n = 9) in the same experimental settings. The inactive vitamin D 3 (cholecalciferal) at 250 nM only had marginal effect in induction of CYP24 expression in this model, it increased CYP24 expression by 27 ± 15 fold (P = 0.12, n = 9), which was statistically insignificant. In this experiment, 1,25(OH) 2 D 3 and cholecalciferal served as a positive and a negative control respectively. These results suggest that 25(OH)D 3 directly activates VDR without being converted to 1,25(OH) 2 D 3 .
Results
Expression
In order to further confirm the direct interaction between 25(OH)D 3 and VDR, we treated T47D breast cancer cells with clotrimazol, a specific 1a-hydroxylase inhibitor to inhibit 1a-hydroxylase activity [24] . Results obtained from these studies would provide evidence whether 25(OH)D 3 without conversion to 1,25(OH)2D 3 is active in inducing CYP24 expression. Results showed that 25(OH)D 3 induced CYP24 mRNA expression in a dose-dependent manner (Fig. 3b) ; surprisingly, the presence of 1 lM clotrimazol consistently and significantly enhanced the 25(OH)D 3 induced CYP24 expression by 10.2-fold (at 100 nM of 25(OH)D 3 ) (from arbitrary unit of 1552 ± 120 (SEM) to 15826 ± 723) and 4.3-fold (at 250 nM of 25(OH)D 3 ) (from 7643 ± 252 to 32768 ± 895) respectively (P \ 0.01, n = 3) (Fig. 3b) . Clotrimazol also enhanced 1,25(OH) 2 D 3 (10 nM) induced CYP24 expression by 10.6-fold (from 2896 ± 150 to 30574 ± 982) (P \ 0.01). Consistent results were also obtained when clotrimazol concentration was increased to 5 lM and in the presence of another 1a-hydroxylase inhibitor, ketoconazol in T47D and MCF-7 cells (data not shown). These results demonstrate that 25(OH)D 3 directly binds to VDR and induce CYP24 expression, although 1,25(OH) 2 D 3 is more active than 25(OH)D 3 . These results do not support the possibility that clotrimazol may be stimulatory for CYP24 expression since treatment with clotrimazol in the absence of vitamin D metabolites did not enhance CYP24 expression.
25(OH)D 3 inhibits DMBA induced precancerous lesion formation
We first conducted experiments to evaluate the efficacy of 25(OH)D 3 in comparison to 1,25(OH) 2 D 3 using MMOC. Table 1 shows the efficacy of 25(OH)D 3 for MAL induced by DMBA. MAL were observed in 18 glands out of 24 (75% incidence) after DMBA treatment. Incubation of glands in the presence of 100 nM and 500 nM 25(OH)D 3 resulted in 61.2% (P \ 0.01) and 57.3% (P \ 0.01) suppression respectively, while 1,25(OH) 2 D 3 at 100 nM resulted in 82% (P \ 0.001) suppression. Representative photograph showing MAL in DMBA treated glands, control glands not treated with DMBA (no lesions) and vitamin D metabolites-treated glands (with fewer lesions) are shown in Fig. 4a-d . Incubation of glands in the presence of 100 nM inactive vitamin D 3 (Cholecalciferol, negative control) only decreased the incidence by 20%, which is not statistically significant (P [ 0.05). We also evaluated the efficacy of 1a(OH)D 3 , which is physiologically not available but served as another control for We next evaluated the efficacy of 25(OH)D 3 for MDL. The MDL were induced by DMBA by including 0.001 lg/ml estradiol and 1 lg/ml progesterone in the medium. These steroid hormones replaced aldosterone and hydrocortisone in the medium. As shown in Table 2 Fig. 4e-g . These results demonstrate that 25(OH)D 3 inhibits both hormone-independent MAL and hormone-dependent MDL.
25(OH)D 3 preferentially inhibits MAL at the promotion stage of carcinogenesis
In order to evaluate the stage-specific efficacy of 25(OH)D 3 on the development of DMBA-induced lesion formation, 14-15 glands per group were incubated with a MAL-promoting hormone combination with or without 250 nM 25(OH)D 3 . 25(OH)D 3 was included in the medium during either the initiation phase from day 0 to day 4 of culture or the promotion phase from day 4 to day 10 of the culture period (Fig. 1). For comparison, 25(OH)D 3 was also included in the medium during both initiation and promotion phase (day 0-day 10) in a group. 1,25(OH) 2 D 3 served as a positive control as anti-promotion agent, whereas aspirin served an anti-initiation agent in the experiments. As shown in Table 3 , the DMBA treated glands in this series of experiments developed MAL in 86.7% (13 out of 15 glands) of the glands. This incidence is consistent with our previous results evaluating effects of DMBA on more than 1500 mammary glands, where the incidence of DMBA induced mammary lesions range from 60 to 100% [5, 19, 20] treatment seems to increase the expression of 1a-hydroxylase. To our knowledge, this is the first report to demonstrate 1a-hydroxylase expression in cultured normal and preneoplastic mouse mammary glands and enhanced expression in the presence of 25(OH)D 3 . It was reported that 1a-hydroxylase is expressed in both normal human breast tissue and breast cancer tissue, but the expression of 1a-hydroxylase in breast cancer tissue is either higher or similar to normal breast epithelial cells [24, 30, 31] . These results from human samples are in agreement with our observation in MMOC. Our RT-PCR analysis of mRNA extracted from cultured mammary glands also confirmed CYP27B1 expression at mRNA level and it was upregulated by 25(OH)D 3 . It should be noted that multiple negative VDRE were identified in the promoter region of CYP27B1 in kidney HEK-293 cells, in which CYP27B1 is downregulated by 1,25(OH) 2 D 3 [32, 33] . However, in breast cancer MCF-7 cells, the altered expression of CYP27B1 by 1,25(OH) 2 D 3 is not significant, suggesting a tissue/cell type specific regulation of CYP27B1 expression [32, 34] . In [21] . Thus, the significant induction of CYP24 observed in the mammary glands obtained from CYP27B1KO mice must be directly from 25(OH)D 3 . These results suggest that 25(OH)D 3 directly binds to VDR and activates CYP24 transcription. Our observation differs from the previous study using mammary cells derived from CYP27B1 null mice [34] , in which, no CYP24 induction by 25(OH)D 3 was observed. These differences could be attributed to 1) the use of different model systems (organ culture vs. cell culture); 2) difference in concentrations of vitamin D metabolites (250 nM 25(OH)D 3 in the present study vs. 100 nM 25(OH)D 3 in the published report) and 3) different measurements (CYP24 mRNA detection in our studies as compared to CYP24 protein detection in the published report). We preferred using sensitive qRT-PCR to detect CYP24 mRNA expression after 25(OH)D 3 since VDR is a transcription factor and directly acts on CYP24 promoter. In addition, we further observed that 1a-hydroxylase inhibitor clotrimazol enhanced CYP24 expression induced by both 25(OH)D 3 and 1,25(OH) 2 D 3 . It is realized that these results using clotrimazol is not conclusive since it might not be a specific 1a-hydroxylase inhibitor. Yet, our results indicate that the inhibition of the activity of both 1a-hydroxylase and 24-hydroxylase did not affect the expression of CYP24, indicating that 25(OH)D 3 activates CYP24 expression by directly binding to VDR. These results also suggest that clotrimazol probably inhibits both metabolism and catabolism of 25(OH)D 3 , extend the half life of 25(OH)D 3 , and in turn increases its direct effect in CYP24 induction. Similar results were also reported with other 1a-hydroxylase inhibitors such as VID400 or SDZ88-357 [16] . These data suggest that 25(OH)D 3 mediates its functional role through both activation of VDR by direct binding to VDR and via activation of VDR by the formation of active metabolite 1,25(OH) 2 D 3 after 1a-hydroxylation. Therefore in the absence of 1a-hydroxylase inhibitor clotrimazol, what we observed could be the mixed role of both 25(OH)D 3 and 1,25(OH) 2 D 3 . Indeed, it was previously reported that 25(OH)D 3 binds to VDR with low affinity, but the binding affinity has been reported to be tissue specific [35, 36] . In agreement with our observation, 25(OH)D 3 has recently been reported to suppresses PTH synthesis by parathyroid cells, possibly by direct activation of the VDR [37] .
Our data also show that 25(OH)D 3 at concentration of 100-250 nM is efficacious in inhibiting both ovarian hormone independent MAL and estrogen and progesterone dependent MDL development. Since 25(OH)D 3 is non- [34] . It should be noted that the concentration of 25(OH)D 3 used in some of the current experiments is within the physiological range. Interestingly, higher concentration (500 nM, Table 1 ) did not enhance the inhibition over that of 100 nM physiological concentration. These results suggest that maintenance of normal physiological concentration of 25(OH)D 3 in the serum will generate protective effect against carcinogenesis, providing direct evidence in support of the epidemiological research [7] . Regarding the physiological concentration of 25(OH)D 3 , generally 80-200 nmol/l (32-80 ng/ml) is considered as vitamin D sufficient physiological concentration [38] . In our studies we used 250 nM 25(OH)D 3 which is considered physiologically achievable and not toxic concentration for this prohormone. Studies performed on subpopulations living or working in sun-rich environments have shown that exposure to sunlight without dietary supplementation can raise 25(OH)D 3 above 200 nM [39] .
It should also be noted that in serum in vivo, as much as 99% of 25(OH)D 3 is bound to the vitamin D binding protein (DBP), and cellular uptake of this complex in the kidney via receptor-mediated endocytosis is essential for vitamin D homeostasis in vivo [40, 41] . Vitamin D is transduced by two separate routes of uptake; active uptake in the presence of DBP and passive uptake in the absence of DBP. In our system, it appears that the passive uptake plays a major role, since vitamin D is lipid-soluble, it can directly diffuse into the cells and mediate its functional role. Active endocytosis seems to take place in the kidney based on literature It has also been reported that normal murine mammary tissue, nontransformed human mammary epithelial cells and some established breast cancer cell lines express megalin and cubilin, which are involved in active uptake of 25(OH)D 3 -DBP complex. These results suggest that endocytosis of DBP is associated with activation of VDR by 25(OH)D 3 in human mammary epithelial cells [42] . However more studies are needed to define the endocytosis of vitamin D metabolites.
Two distinct vitamin D 3 endocrine systems have recently been proposed [16] . The first one is the classical system involved in calcium and phosphorus regulation based on 1,25(OH) 2 D 3 . The formation of 1,25(OH) 2 D 3 is tightly controlled in kidney and the concentration in serum varies with an extremely narrow range. The alternative vitamin D 3 endocrine system involved in cell proliferation and differentiation regulation and maintenance of homeostasis is based on 25(OH)D 3 , which is mainly generated in the liver and maintained at high levels in circulation and fluctuates within a wide range. The prohormone 25(OH)D 3 can be metabolized to 1,25(OH) 2 D 3 in extrarenal tissues. Our data support this hypothesis in relation to 25(OH)D 3 . However, we also propose that 25(OH)D 3 plays a direct functional role in maintaining homeostasis in mammary gland and can serve as a natural preventive agent for carcinogenesis. A modified hypothesis of action of 25(OH)D 3 in relation to breast cancer chemoprevention is presented in Fig. 5 .
In summary, we found that 1a-hydroxylase is expressed in mouse mammary epithelial cells and that 25(OH)D 3 could directly activate VDR. At physiological concentration, 25(OH)D 3 inhibits mammary preneoplastic lesion formation induced by DMBA. These results suggest that 25(OH)D 3 , the major circulating form of vitamin D metabolite could be a natural chemopreventive agent against transformation of breast epithelial cells. 
